Clinical trials
Phase 4 Rhinitis, Allergic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
96 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 6 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 74 |
| Unknown status | 8 |
| Withdrawn | 5 |
| Active, not recruiting | 4 |
| Not yet recruiting | 3 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 8 |
| Organon and Co | 6 |
| University of Dundee | 5 |
| University of Chicago | 4 |
| Brian J Lipworth | 3 |
| Medical University of Lodz | 3 |
| Sanofi | 3 |
| Bayer | 2 |
| Bayside Health | 2 |
| Beijing Tongren Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rhinitis, Allergic | 96 |
| Asthma | 17 |
| Rhinitis, Allergic, Seasonal | 7 |
| Rhinitis | 6 |
| Hypersensitivity | 4 |
| Rhinitis, Allergic, Perennial | 4 |
| Dermatitis, Atopic | 2 |
| Urticaria | 2 |
| Chronic Urticaria | 1 |
| Conjunctivitis, Allergic | 1 |
Trials
Showing 76 to 96 of 96. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.